scholarly journals Indirect frontocingulate structural connectivity predicts clinical response to accelerated rTMS in major depressive disorder

2020 ◽  
pp. 243-252
Author(s):  
Deborah C.W. Klooster ◽  
Iris N. Vos ◽  
Karen Caeyenberghs ◽  
Alexander Leemans ◽  
Szabolcs David ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Clinical Response ◽  
Structural Connectivity ◽  
Major Depressive

scholarly journals Microstructural deficits in the thalamus of major depressive disorder

2021 ◽  
Author(s):  
Pengfei Xu ◽  
Gangqiang Hou ◽  
Yuxuan Zhang ◽  
Yingli Zhang ◽  
Hui Ai ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Large Scale ◽  
Gray Matter Volume ◽  
Structural Connectivity ◽  
Brain Network ◽  
Microstructural Properties ◽  
Major Depressive ◽  
T1 Relaxation ◽  
Structural Abnormalities

Macroscopic structural abnormalities in the thalamus and thalamic circuits have been shown to contribute to the neuropathology of major depressive disorder (MDD). However, cytoarchitectonic properties underlying these macroscopic abnormalities remain unknown. The purpose of this study was to identify systematic deficits of brain architecture in depression, from structural brain network organization to microstructural properties. A multi-modal neuroimaging approach including diffusion, anatomical and quantitative magnetic resonance imaging (MRI) was used to examine structural-related alternations in 56 MDD patients compared with 35 age- and sex-matched controls. Structural networks were constructed and analyzed using seed-based probabilistic tractography. Morphometric measurements, including cortical thickness and voxel-based morphometry (VBM), were evaluated across the whole brain. A conjunction analysis was then conducted to identify key regions showing common structural alternations across modalities. The microstructural properties, macromolecular tissue volume (MTV) and T1 relaxation times of identified key regions were then calculated. Results showed multiple alterations of structural connectivity within a set of subcortical areas and their connections to cortical regions in MDD patients. These subcortical regions included the putamen, thalamus and caudate, which are predominately involved in the limbic-cortical-striatal-pallidal-thalamic network (LCSPT). Structural connectivity was disrupted within and between large-scale networks, mainly including subcortical networks, default mode networks and salience/ventral attention networks. Consistently, these regions also exhibited widespread volume reductions in MDD patients, specifically the bilateral thalamus, left putamen and right caudate. Importantly, the microstructural properties, T1 relaxation time of left thalamus were increased and negatively correlated with its gray matter volume in MDD patients. The present work to date sheds light on the neuropathological disruptions of LCSPT circuit in MDD, providing the first multi-modal neuroimaging evidence for the macro-micro structural abnormalities of the thalamus in patients with MDD. These findings have implications in understanding the abnormal changes of brain structures across development of MDD.

Psychiatric Comorbidity as a Predictor of Clinical Response to Nortriptyline in Treatment-Resistant Major Depressive Disorder

2003 ◽  
Vol 64 (11) ◽  
pp. 1357-1361 ◽  
Author(s):  
George I. Papakostas ◽  
Timothy J. Petersen ◽  
Amy H. Farabaugh ◽  
Jessica L. Murakami ◽  
Joel A. Pava ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Clinical Response ◽  
Psychiatric Comorbidity ◽  
Treatment Resistant ◽  
Major Depressive

scholarly journals Relationship between body mass and clinical response to repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder

2019 ◽  
Vol 11 (1) ◽  
pp. 18-21
Author(s):  
Maria Cristina Davila ◽  
Brianna Ely ◽  
Ann M. Manzardo
Keyword(s):  
Body Composition ◽  
Major Depressive Disorder ◽  
Transcranial Magnetic Stimulation ◽  
Depressive Disorder ◽  
Clinical Response ◽  
Body Mass ◽  
Magnetic Stimulation ◽  
Remission Rate ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Major Depressive

Repetitive transcranial magnetic stimulation (rTMS) has been proven to be efficacious in the treatment of Major Depressive Disorder (MDD). We previously examined the effectiveness of rTMS for MDD in an applied clinical setting, AwakeningsKC Clinical Neuroscience Institute (CNI) and found high remission rates for patients diagnosed with MDD following rTMS treatment. An unexpected relationship with body composition and rTMS unit was discovered. This sub-study extends the previous investigation through a focused analysis of the effects of body composition on response to rTMS in the treatment of MDD. We utilized data collected from a retrospective review of medical records for patients diagnosed with MDD undergoing rTMS therapy at AwakeningsKC CNI. Patient Health Questionnaire 9 (PHQ-9) scores, time to remission status and body mass index (BMI) at baseline were considered while referencing two different rTMS instruments (MagVenture; NeuroStar). We found 23 (9%) of 247 participants met criteria for obese status (BMI?30) with an average baseline PHQ-9 score of 22±4, classified as “severe depression”. Obesity status was differentially impacted by the rTMS instrument used for treatment. Patients with obesity showed a shorter time to remission (mean 2.7±0.27 vs. mean 3.4±0.3 weeks) and proportionately greater remission rate (100% vs. 71%) when treated using the MagVenture relative to the NeuroStar instrument. Clinical response to rTMS therapy for MDD appears to be guided by individual factors including body composition and rTMS parameters such as the unit used for treatment. Further study of these influences could aid in the optimization of clinical response to rTMS.

Increased mitogen-stimulated lymphocyte proliferation is associated with the clinical response in major depressive disorder in women: A follow-up study

2016 ◽  
Vol 239 ◽  
pp. 220-221
Author(s):  
Antti-Pekka Elomaa ◽  
Heimo Viinamäki ◽  
Ilkka T. Harvima ◽  
Heli Koivumaa-Honkanen ◽  
Kirsi Honkalampi ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Clinical Response ◽  
Lymphocyte Proliferation ◽  
Major Depressive ◽  
Follow Up Study

scholarly journals Relationship between body mass and clinical response to repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Maria Cristina Davila ◽  
Brianna Ely ◽  
Ann M. Manzardo
Keyword(s):  
Body Composition ◽  
Major Depressive Disorder ◽  
Transcranial Magnetic Stimulation ◽  
Depressive Disorder ◽  
Clinical Response ◽  
Body Mass ◽  
Magnetic Stimulation ◽  
Remission Rate ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Major Depressive

Repetitive transcranial magnetic stimulation (rTMS) has been proven to be efficacious in the treatment of Major Depressive Disorder (MDD). We previously examined the effectiveness of rTMS for MDD in an applied clinical setting, AwakeningsKC Clinical Neuroscience Institute (CNI) and found high remission rates for patients diagnosed with MDD following rTMS treatment. An unexpected relationship with body composition and rTMS unit was discovered. This sub-study extends the previous investigation through a focused analysis of the effects of body composition on response to rTMS in the treatment of MDD. We utilized data collected from a retrospective review of medical records for patients diagnosed with MDD undergoing rTMS therapy at AwakeningsKC CNI. Patient Health Questionnaire 9 (PHQ-9) scores, time to remission status and body mass index (BMI) at baseline were considered while referencing two different rTMS instruments (MagVenture; NeuroStar). We found 23 (9%) of 247 participants met criteria for obese status (BMI≥30) with an average baseline PHQ-9 score of 22±4, classified as “severe depression”. Obesity status was differentially impacted by the rTMS instrument used for treatment. Patients with obesity showed a shorter time to remission (mean 2.7±0.27 vs. mean 3.4±0.3 weeks) and proportionately greater remission rate (100% vs. 71%) when treated using the MagVenture relative to the NeuroStar instrument. Clinical response to rTMS therapy for MDD appears to be guided by individual factors including body composition and rTMS parameters such as the unit used for treatment. Further study of these influences could aid in the optimization of clinical response to rTMS.

Sign in / Sign up

Export Citation Format

Share Document